【レポートの概要（一部）】
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 11
2 Pharmaceuticals & Healthcare, Global, Deal Summary, Q2 2013 15
2.1 Pharmaceuticals & Healthcare, Global, Deals Analysis, Q2 2013 15
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals, Q2 2013 18
2.3 Pharmaceuticals & Healthcare, Global, by Type, Deal Values, Q2 2013 19
2.4 Pharmaceuticals & Healthcare, Global, Top Deals, Q2 2013 20
2.4.1 Life Technologies Receives Shareholders Approval for Its Acquisition by Thermo Fisher Scientific for US$13.6 Billion 20
2.4.2 Valeant Pharma Completes Acquisition of Bausch & Lomb for US$ 8.7 Billion 22
2.4.3 Actavis Receives French Competition Authority Approval to Acquire Warner Chilcott for US$8.5 Billion 23
2.4.4 Merck Completes Public Offering of Notes for US$6.5 Billion 24
2.4.5 Tenet Healthcare to Acquire Vanguard Health Systems for US$4.3 Billion 25
3 Pharmaceuticals & Healthcare, Global, Deals Summary, by Type 26
3.1 Pharmaceuticals & Healthcare, Global, M&A, Q2 2013 26
3.1.1 Top M&A Deals in Q2 2013 28
3.1.2 Pharmaceuticals & Healthcare, Global, M&A Deals, by Therapy Area, Q2 2012 – Q2 2013 29
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q2 2013 31
3.2.1 Top Initial Public Offerings in Q2 2013 32
3.2.2 Top Secondary Offerings in Q2 2013 32
3.2.3 Top PIPE Deals in Q2 2013 33
3.2.4 Pharmaceuticals & Healthcare, Global, Top IPOs Share Performance, Q2 2012-Q2 2013 33
3.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q2 2012 – Q2 2013 34
3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q2 2013 36
3.3.1 Top Venture Financing Deals in Q2 2013 37
3.3.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q2 2013 38
3.3.3 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q2 2013 39
3.3.4 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q2 2012 – Q2 2013 40
3.3.5 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Last Four Quarters 42
3.3.6 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Last One Year 44
3.4 Pharmaceuticals & Healthcare, Global, Private Equity Deals, Q2 2013 45
3.4.1 Top Private Equity Deals in Q2 2013 46
3.4.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q2 2012 – Q2 2013 47
4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q2 2013 49
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q2 2013 49
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q2 2012 – Q2 2013 51
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2013 53
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Values, Q2 2013 54
4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q2 2013 55
4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payments, Q2 2013 56
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2012 – Q2 2013 57
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals, Q2 2012 – Q2 2013 59
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Deal Values (US$ m), Q2 2012 – Q2 2013 60
4.7 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payments and Deal Values (US$ m), Q2 2012 – Q2 2013 62
5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q2 2013 64
5.1 Pharmaceutical & Healthcare, Global, Licensing Agreements, Q2 2013 64
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payments and Deal Values (US$ m), Q2 2012 – Q2 2013 66
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q2 2013 68
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payments, Q2 2013 68
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q2 2013 69
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q2 2012 – Q2 2013 70
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payments Vs Milestone Payments (US$ m), Q2 2012 – Q2 2013 72
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q2 2012 – Q2 2013 74
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Values (US$ m), Q2 2012 – Q2 2013 75
5.7 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payments Vs Milestone Payments (US$ m), Q2 2012 – Q2 2013 77
6 Pharmaceuticals & Healthcare, Global, M&A Financial Analysis 79
6.1 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value versus Median Deal Value, Q2 2012 – Q2 2013 79
6.2 Pharmaceuticals& Healthcare, Global Acquisitions, Average Price Earnings of Acquired Companies, Q2 2012 – Q2 2013 81
6.3 Pharmaceuticals & Healthcare, Global Acquisitions, Average EV/EBITDA of Acquired Companies, Q2 2012 – Q2 2013 83
6.4 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value per Operating Profit, Q2 2012 – Q2 2013 85
6.5 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Market Price Per Share, Q2 2012 – Q2 2013 87
6.6 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Share versus Average Book Value Per Share, Q2 2012 – Q2 2013 89
6.7 Pharmaceuticals & Healthcare, Global Acquisitions, Average Deal Value Per Sales, Q2 2012 – Q2 2013 90
7 Pharmaceuticals & Healthcare, Global, Deal Summary by Therapy Area 92
7.1 Pharmaceuticals & Healthcare, Global, Oncology Deals, Q2 2013 92
7.1.1 Oncology – Deals of the Quarter 94
7.2 Pharmaceuticals & Healthcare, Global, Central Nervous System Deals, Q2 2013 96
7.2.1 Central Nervous System – Deals of the Quarter 98
7.3 Pharmaceuticals & Healthcare, Global, Infectious Disease Deals, Q2 2013 99
7.3.1 Infectious Disease – Deals of the Quarter 101
7.4 Pharmaceuticals & Healthcare, Global, Immunology Deals, Q2 2013 103
7.4.1 Immunology – Deals of the Quarter 105
7.5 Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals, Q2 2013 106
7.5.1 Metabolic Disorders – Deals of the Quarter 108
7.6 Pharmaceuticals & Healthcare, Global, Cardiovascular Deals, Q2 2013 110
7.6.1 Cardiovascular – Deals of the Quarter 112
7.7 Pharmaceuticals & Healthcare, Global, Gastrointestinal Deals, Q2 2013 114
7.7.1 Gastrointestinal – Deals of the Quarter 116
7.8 Pharmaceuticals & Healthcare, Global, Ophthalmology Deals, Q2 2013 117
7.8.1 Ophthalmology – Deals of the Quarter 119
7.9 Pharmaceuticals & Healthcare, Global, Respiratory Deals, Q2 2013 120
7.9.1 Respiratory – Deals of the Quarter 122
7.10 Pharmaceuticals & Healthcare, Global, Dermatology Deals, Q2 2013 124
7.10.1 Dermatology – Deals of the Quarter 126
8 Deal Summary by Geography 127
8.1 Pharmaceuticals & Healthcare, North America Region, Deals, Q2 2013 127
8.1.1 North America – Deals of the Quarter 129
8.2 Pharmaceuticals & Healthcare, Europe Region, Deals, Q2 2013 132
8.2.1 Europe – Deals of the Quarter 134
8.3 Pharmaceuticals & Healthcare, Asia-Pacific, Deals, Q2 2013 136
8.3.1 Asia-Pacific – Deals of the Quarter 138
8.4 Pharmaceuticals & Healthcare, Rest of the World, Deals, Q2 2013 139
8.4.1 Rest of the World – Deals of the Quarter 141
9 Pharmaceuticals & Healthcare, Global, Top Advisors 143
9.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Last One Year 143
9.2 Pharmaceuticals & Healthcare, Global, Top Financial Advisors, Equity Offerings, Last One Year 145
10 Appendix 147
11 Further Information 151
11.1 Methodology 151
11.2 About GlobalData 152
11.3 Disclosure information 153
11.4 Disclaimer 153
【レポート販売概要】
■ タイトル：事業提携・ライセンシング・投資・M&A動向（四半期別）：Q2 2013■ 英文：Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q2 2013
■ 発行日：2013年8月31日
■ 調査会社：GlobalData
■ 商品コード：GDATA403161917
■ 調査対象地域：グローバル
- Ascites：グローバル臨床試験レビューH1, 2013Ascites Global Clinical Trials Review, H1, 2013 Summary GlobalData's clinical trial report, “Ascites Global Clinical Trials Review, H1, 2013" provides data on the Ascites clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Ascites. It includes an overview of the trial numbers and their recruitment status as per the site of trial conductio …
- 左心耳（LAA）閉鎖デバイスの世界市場2016-2020The left atrial appendage (LAA) is a small ear-shaped sac in the muscle wall of the top left chamber of the heart that controls the electrical impulses during atrial fibrillation. LAA closure device is an interventional device used to prevent stroke, reduce the risk of secondary stroke and emboli because of atrial fibrillation. The global left atrial appendage closure market is expected to grow at …
- ココナッツミルクの世界市場2016-2020About Coconut MilkCoconut milk is a sweet, milky white liquid obtained from the grated meat of mature coconut. The rich taste and color of coconut milk can be attributed to the high oil and sugar contents in it. It is one of the main ingredients of Southeast Asian cuisine and is used for making curries, deserts, and sweets. Coconut milk is consumed as a drink and is also used as a cooking ingredie …
- 世界のROADMコンポーネント市場動向（2012-2016）TechNavio's analysts forecast the Global ROADM Component market to grow at a CAGR of 29.22 percent over the period 2012-2016. One of the key factors contributing to this market growth increasing need to manage network traffic. The Global ROADM Component market has also been witnessing growing popularity of ROADM components in China. However, worsening economic conditions could pose a challenge to …
- 金属くず用シュレッダーの世界市場2017-2021ABSTRACTAbout Scrap Metal Shredder An industrial shredder can shred all kinds of materials such as tires, car wrecks, metals, plastics, wood, and garbage. However, the shredding process depends on the machine's design and size. Shredders are available in numerous sizes and designs. Design variations include horizontal hammer mills, vertical hammer mills, and slow speed and shear-type shredders of …
- Empresa Nacional de Electricidad S.A.：発電所及びSWOT分析2013Empresa Nacional de Electricidad S.A. - Power Plants and SWOT Analysis, 2013 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executives), and major products and services. Scope - Major Power Plants (assets …
- FRP/GRP/GREパイプの世界市場：ポリエステル、ポリウレタン、エポキシ、ガラス繊維、炭素繊維The global FRP pipe market size in terms of value is projected to grow at a CAGR of 3.5% between 2015 and 2020 to reach $4 billion by 2020. Asia-Pacific held the largest share in FRP pipe market in 2014. Major growth in Asia-Pacific FRP pipe market is due to the growth opportunities, considering significant demands from end application industries as chemical, oil and gas, retail fuel, water/waste …
- 世界のIoNT（Internet of Nano Things）市場：通信種類別/ナノデバイス別/産業別分析The interconnectivity of nanoscale devices with deployed Internet networks has become the centre of all business activities; this is described as Internet of Nano Things (IoNT). It is the essence of smart connectivity of devices implemented for communication. It will help in seamless transfer of data among the devices with the help of a given spectrum. The internetwork of devices will change over …
- 高級デニム製ジーンズの世界市場2016-2020About Premium Denim Jeans The sales of premium denim jeans were mainly from the specialty stores which is a shift from department stores globally. New trends and product innovation in premium range provide prospects for the market growth over the forecast period. Technavio’s analysts forecast the global premium denim jeans market to grow at a CAGR of 8.09% during the period 2016-2020. [Covered in …
- ソリッドコントロール装置の世界市場2015-2022According to Stratistics MRC, the Global Solid control equipment Market is valued at $1.84 billion in 2015 and is expected to grow at a CAGR of 11.41% to reach $3.92 billion by 2022. The rising demand for energy and increasing environmental concerns are the key factors driving the solids control equipment market growth. However adverse weather conditions pose a major challenge for the vendors in t …
- データ暗号化ソフトウェアの世界市場2015-2019About Encryption Software Encryption is a technique that secures data by converting plain text into a cipher format during transmission through the internet. The process uses mathematical algorithms that convert the information into an undecipherable format that can only be accessed using a secret code. The strength of an encryption code is measured by its length, which is determined by the number …
- Diovan (Chronic Heart Failure)：市場予測と分析（～2022）Diovan (Chronic Heart Failure) - Forecast and Market Analysis to 2022 Summary The chronic heart failure (CHF) market is a mature market that has been slowly overtaken by generic drugs, and more branded products are expected to lose market exclusivity during the next few years. GlobalData predicts that the major global barriers that will play a crucial role in narrowing the global growth of the CHF …
- 世界の顧客経験管理（CEM）市場動向、規模及び予測(2014 – 2019)The report has been segmented in such a way that it covers various forms of the market which include simple Customer Experience Management (CEM), Customer Relationship Management (CRM), Social Customer Relationship Management (SCRM), Social Customer Experience Management (SCEM), and Telco Customer Experience Management (Telco CEM). CEM is a collection of process, which uses a variety of technologi …
- 脂肪酸メチルエステルスルホネート（FMES）の世界市場分析：エンドユーザー別（パーソナルケア、洗剤）、地域別（北アメリカ、ヨーロッパ、アジア太平洋、中南米、中東、アフリカ）、競争戦略、セグメント予測The global fatty methyl ester sulfonate (FMES) market is expected to reach USD 2.49 billion by 2025, according to a new report by Grand View Research, Inc. Rising consumer awareness towards cleanliness, hygiene, and health is anticipated to be a major factor for significant market growth for FMES based personal care over the next few years. Growing population coupled with increasing disposable con …
- 自動車用NVH（騒音・振動・ハーシュネス）材料の世界市場：ゴム、熱可塑性ポリマ、エンジニアリング樹脂The global Automotive NVH (Noise Vibration Harshness) materials market size, in terms of value, is projected to reach USD 11.6 Billion by 2020, growing at a CAGR of 5.4% between 2015 and 2020. The increased necessity to reduce noise and vibration from vehicles and governments’ regulations to make quieter & safer vehicle are key factors driving the growth of the global automotive NVH materials mark …
